Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LATS1 | O95835 | 10/20 | 0.72 |
| ▸ | LATS2 | Q9NRM7 | 9/20 | 0.72 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.56 |
| ▸ | PDE5A | O76074 | 2/20 | 0.56 |
| ▸ | POLB | P06746 | 1/20 | 0.56 |
| ▸ | HPGD | P15428 | 1/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.56 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.54 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.53 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.53 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.53 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.53 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.53 |
| ▸ | GBA1 | P04062 | 1/20 | 0.53 |
| ▸ | ACP1 | P24666 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26177113 | 0.84 | LATS1 (1.00) | LATS1LATS2 | |
| SCHEMBL26177114 | 0.81 | LATS1 (1.00) | LATS1LATS2 | |
| SCHEMBL22201649 | 0.78 | KDM4E (0.56) | LATS1LATS2KDM4EALDH1A1PDE5A | |
| SCHEMBL1083972 | 0.74 | ACP1 (0.85) | LATS1LATS2KDM4EALDH1A1PDE5A | |
| SCHEMBL3459938 | 0.74 | LMNA (0.62) | KDM4EALDH1A1PDE5APOLBHPGD | |
| SCHEMBL3460201 | 0.73 | ACP1 (0.84) | LATS1LATS2KDM4EALDH1A1PDE5A | |
| SCHEMBL7434986 | 0.73 | ALDH1A1 (1.00) | LATS1KDM4EALDH1A1PDE5APOLB | |
| SCHEMBL14262837 | 0.73 | KDM4E (0.94) | LATS1KDM4EALDH1A1PDE5APOLB | |
| SCHEMBL20547760 | 0.72 | LATS1 (1.00) | LATS1LATS2 | |
| SCHEMBL3460111 | 0.72 | GBA1 (0.77) | KDM4EALDH1A1PDE5APOLBHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7763627-B2 | Tie-2 modulators and methods of use | EXELIXIS, INC. (US) | 2010-07-27 | — | — | US | disclosed |
| US-20070161651-A1 | Tie-2 modulators and methods of use | EXELIXIS, INC. (US) | 2007-07-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070161651-A1 | Tie-2 modulators and methods of use | TIE1, TEK, KDR | LATS1 1418/4885LATS2 1065/4885KDM4E 486/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.